Abstract
Phosphorylated peptides presented by human leukocyte antigen (HLA) class II molecules play pivotal roles in immune regulation, yet their characterization and prediction remain challenging due to data noise and limited HLA coverage. Here, we introduce NetMHCIIphosPan, a prediction method for HLA-II antigen presentation of phosphorylated peptides, developed using mass spectrometry (MS)-based immunopeptidomics datasets. Employing a refined peptide identification workflow, we reanalyzed earlier HLA-II phospholigand datasets and trained predictive models, achieving superior performance compared to models trained on original data. Binding motif analysis revealed that HLA-specific preferences for phospholigands closely aligned with those of unmodified ligands. Incorporating unmodified ligands into training further enhanced predictive accuracy, particularly for HLA-DP and HLA-DQ molecules. NetMHCIIphosPan outperformed existing tools, such as NetMHCIIpan-4.3 and MixMHC2pred-1.3, for prediction of HLA antigen presentation of phosphorylated peptides demonstrating robustness and utility. This work establishes NetMHCIIphosPan as a state-of-the-art tool for understanding the HLA-II phospholigandome, with potential applications in immunotherapy and vaccine design.
Full text
1,992 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Phosphorylated peptides presented by human leukocyte antigen (HLA) class II molecules play pivotal roles in immune regulation, yet their characterization and prediction remain challenging due to data noise and limited HLA coverage. Here, we introduce NetMHCIIphosPan, a prediction method for HLA-II antigen presentation of phosphorylated peptides, developed using mass spectrometry (MS)-based immunopeptidomics datasets. Employing a refined peptide identification workflow, we reanalyzed earlier HLA-II phospholigand datasets and trained predictive models, achieving superior performance compared to models trained on original data. Binding motif analysis revealed that HLA-specific preferences for phospholigands closely aligned with those of unmodified ligands. Incorporating unmodified ligands into training further enhanced predictive accuracy, particularly for HLA-DP and HLA-DQ molecules. NetMHCIIphosPan outperformed existing tools, such as NetMHCIIpan-4.3 and MixMHC2pred-1.3, for prediction of HLA antigen presentation of phosphorylated peptides demonstrating robustness and utility. This work establishes NetMHCIIphosPan as a state-of-the-art tool for understanding the HLA-II phospholigandome, with potential applications in immunotherapy and vaccine design.
Competing Interest Statement
The authors have declared no competing interest.
Abbreviations
- HLA
- Human Leukocyte Antigen
- HLA-II
- Human Leukocyte Antigen class II
- MS
- Mass Spectrometry
- MHC
- Major Histocompatibility Complex
- ML
- Machine Learning
- PTM
- Post-Translational Modification
- SA
- Single-Allele
- MA
- Multi-Allele
- BA
- Binding Affinity
- EL
- Eluted Ligand
- PH
- Phosphopeptide
- UM
- Unmodified peptide
- FPR
- False Positive Rate
- ROC-AUC
- Receiver Operating Characteristic - Area Under the Curve
- ROC-AUC 0.1
- Receiver Operating Characteristic - Area Under the Curve integrated up to a 0.1
- FPR PPV
- Positive Predictive Value
- PR-AUC
- Precision-Recall - Area Under the Curve
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.